These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24094090)

  • 1. A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.
    Taguchi A; Maruyama H; Nameta M; Yamamoto T; Matsuda J; Kulkarni AB; Yoshioka H; Ishii S
    Biochem J; 2013 Dec; 456(3):373-83. PubMed ID: 24094090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
    Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
    PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model.
    Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Sakiyama Y; Muramatsu K; Mizukami H
    Hum Gene Ther; 2024 Mar; 35(5-6):192-201. PubMed ID: 38386497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
    Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
    J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in α-galactosidase A-deficient mice.
    Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Muramatsu K; Sakiyama Y; Mizukami H
    J Gene Med; 2023 Dec; 25(12):e3560. PubMed ID: 37392007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An in vitro model of Fabry disease.
    Shu L; Murphy HS; Cooling L; Shayman JA
    J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
    Shu L; Shayman JA
    J Biol Chem; 2007 Jul; 282(29):20960-7. PubMed ID: 17535804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
    Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
    Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered globotriaosylceramide accumulation and mucosal neuronal fiber density in the colon of the Fabry disease mouse model.
    Masotti M; Delprete C; Dothel G; Donadio V; Rimondini R; Politei JM; Liguori R; Caprini M
    Neurogastroenterol Motil; 2019 Mar; 31(3):e13529. PubMed ID: 30609268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
    Choi JO; Lee MH; Park HY; Jung SC
    J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences in cleavage of globotriaosylceramide and its derivatives accumulated in organs of young Fabry mice following enzyme replacement therapy.
    Kodama T; Tsukimura T; Kawashima I; Sato A; Sakuraba H; Togawa T
    Mol Genet Metab; 2017; 120(1-2):116-120. PubMed ID: 27756537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
    Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
    PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
    Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
    Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
    Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
    Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
    Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
    PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of alpha-galactosidase A upregulates CD77: functional impact for Fabry nephropathy.
    Thomaidis T; Relle M; Golbas M; Brochhausen C; Galle PR; Beck M; Schwarting A
    Kidney Int; 2009 Feb; 75(4):399-407. PubMed ID: 19037253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease.
    Shin YJ; Jeon YJ; Jung N; Park JW; Park HY; Jung SC
    Mol Med Rep; 2015 Oct; 12(4):5049-57. PubMed ID: 26135632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer.
    Park J; Murray GJ; Limaye A; Quirk JM; Gelderman MP; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3450-4. PubMed ID: 12624185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.